Members include Nobel laureate James P. Allison, Padmanee Sharma, Taha Merghoub, and Kingston Mills, who are all globally renowned experts in cancer im...
Superior efficacy and favorable tolerability in animal models support the potential of ARR-002 to overcome limitations of single-target approaches Pha...
- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid’s integrated, multi-trial development p...
Transaction Adds Dual BBB Delivery Strategies, Supports Alzheimer's Programs, Combination Therapies, 505(b)(2) Pathways, and CNS Countermeasure Applicati...
FreeMind Investments (FMI), a venture capital fund launched in partnership between FreeMind Group and Daewoong Pharmaceutical Co., Ltd., announced its in...
Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi®(ruxolitinib) Once-daily Jakafi XR was shown to provide consisten...
Deal builds upon UCB’s position as a leader in immunology innovation and expands capabilities in next-generation biologics with potential for i...
InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the pr...
Central nervous system (CNS) cancers remain among the most difficult diseases to treat in oncology, with limited therapeutic options, complex deliv...
As pharmaceutical companies continue to face high attrition rates, rising development costs and increasingly complex clinical datasets, the industry is sea...
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administra...
TrialClinIQ, an AI-powered clinical trial recruitment platform based in Houston, Texas advancing health equity, announced a $150K pre-seed investment fro...
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that its pivotal Phase 3 cl...
Validates platform's ability to rapidly iterate across immune cell types Leverages novel NK and myeloid co-programming architecture to deliver coordin...
© 2026 Biopharma Boardroom. All Rights Reserved.
